Skip to main content
OpenTrials
Completed

NCT Number: NCT04451811

A PK Dose Proportionality Study of OPL-002 in Healthy Volunteers

This is a single center, randomized, open-label, three-way crossover, single dose, pharmacokinetic dose proportionality study of oral OPL-002 in healthy subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Celerion

Belfast, Northern Ireland, BT9 6AD, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female (of non-childbearing potential only) between 18 and 55 years of age.
  • Females must be of non-childbearing potential and must have undergone one of the following sterilization procedures, and have official documentation, at least 6 months prior to the first dose:
  • hysteroscopic sterilization;
  • bilateral tubal ligation or bilateral salpingectomy;
  • hysterectomy;
  • bilateral oophorectomy, or;
  • be postmenopausal with amenorrhea for at least 1 year prior to the first dose and have FSH serum levels consistent with postmenopausal status as per investigator judgment.
  • Male subjects must use reliable forms of contraception from screening to 30 days after the end of dosing.
  • Good general health as determined by medical history, and by results of physical examination, vital signs, ECG, and clinical laboratory tests obtained within 28 days (4 weeks) prior to study drug administration.

Exclusion criteria

  • History or presence of any clinically significant organ system disease that could interfere with the objectives of the study or the safety of the subjects.
  • pressure and heart rate are outside the ranges 90-140 mmHg systolic, 40-90 mmHg diastolic, heart rate 60-100 beats/min.
  • 12-lead ECG with any abnormality judged by the Investigator to be clinically significant, QRS >= 110 milliseconds (msec), QT/QTcF interval of > 450 msec for men or >470 msec for women, or PR > 200 msec.
  • Presence or history of any abnormality or illness, which in the opinion of the Investigator may affect absorption, distribution, metabolism or elimination of the study drug.

Treatment and study plan

OPL-002

Drug

Spray dried dispersion and tablet formulation

Primary outcomes

  1. AUC of OPL-002

    Time frame: 0 to 48 hours

Secondary outcomes

  1. Dose proportionality of 5 and 20 mg

    Time frame: 0 to 48 hours

  2. Absolute lymphocyte count

    Time frame: 0 to 48 hours

Sponsors and collaborators

Lead sponsor

Oppilan Pharma Ltd

Industry

Collaborators

  • Celerion

Registry information

Official study title

A Pharmacokinetic Dose Proportionality Study of OPL-002 in Healthy Volunteers

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Jun 30, 2020
Registry last updated
May 28, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.